Third-party certification is one of the best ways to ensure that suppliers meet recognised standards. It lends credibility to the sector and offers reassurance to both customers and consumers. Most tissue producers support the different international and national forest certification schemes and over 80%of the forests owned by paper and lumber companies in


For the first time, the World Health Organization has officially listed the Ministry of Health, Labor, and Welfare/Pharmaceuticals and Medical Devices Agency (MHLW/PMDA) of Japan, Health Canada, and the Medicines and Healthcare Products Regulatory Agency (MHRA) of the UK as the new WHO-listed authorities (WLAs), a status that is granted to national authorities that meet the highest international regulatory benchmarks when it comes to medical products.
With these latest designations, WHO goes on to expand the growing list of WLAs, which now involves 39 agencies throughout the world, thereby supporting a broader and faster access to quality-assured medical products, especially in low- as well as middle-income countries.
Besides this, the Ministry of Food and Drug Safety (MFDS) of the Republic of Korea, which is one of the first regulatory authorities to complete the WLA evaluation for medicines as well as vaccines in October 2023, has got its listing scope successfully expanded, therefore now covering all the regulatory functions.
According to Dr. Tedros Adhanom Ghebreyesus, who is the director-general of the World Health Organization, this recognition goes on to reflect the deep commitment of these authorities towards regulatory excellence. The designation as new WHO-listed authorities is not just a testament to their robust systems concerning regulations but also a crucial contribution that they make towards global public health. He added that robust and dependable regulators help in ensuring that people across the world have access to effective, safe, and high-quality medical products.
It is well to be noted that almost 70% of the countries across the world still face prominent challenges because of weak or inadequate regulatory systems when it comes to evaluating as well as authorizing their medical products. The WLA framework goes on to promote regulatory convergence and international collaboration, thereby helping the WHO prequalification program and regulatory authorities, especially those who are located in low- and middle-income countries so as to depend on the trusted work as well as the decisions of certain designated agencies. This kind of partnership supports the efficient usage of limited resources, therefore helping with better and faster access in terms of quality-assured, life-saving medical products for billions more people.
